Trial · NCT03932981
First-line Chemotherapy With Temozolomide Alone for Non-enhancing Adult Brainstem Gliomas, With a Diffuse Subtype and Showing Clinical and/or Radiological Infiltrative Pattern of Progression
NCT03932981, Phase 2, Unknown, Assistance Publique - Hôpitaux de Paris
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. First-line Chemotherapy With Temozolomide Alone for Non-enhancing Adult Brainstem Gliomas, With a Diffuse Subtype and Showing Clinical and/or Radiological Infiltrative Pattern of Progression. Trials, record NCT03932981. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03932981
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- First-line Chemotherapy With Temozolomide Alone for Non-enhancing Adult Brainstem Gliomas, With a Diffuse Subtype and Showing Clinical and/or Radiological Infiltrative Pattern of Progression
- NCT number
- NCT03932981
- Status
- Unknown
- Phases
- Phase 2
- Enrollment
- 60 participants, estimated
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Conditions
- Adult Brainstem Glioma
- Interventions
- Temozolomide
- First posted
- 2019-05-01
- Last updated
- 2021-09-10
- Other registries' IDs
- eudract:2018-002654-79
Source ClinicalTrials.gov
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Objective response rate based on best response (Complete Response (CR) and Partial Response (PR)) to Temozolomide according to RANO criteria. | Baseline, every month for up to 12 months from start of treatment | A patient will be considered to be in an objective response to Temozolomide if the best response is a complete or partial response defined according to the RANO criteria. |
| Secondary | Progression-free survival | 15 months or later, up to 48 months | |
| Secondary | Histological pattern of adult brainstem gliomas | 15 months | Description of the histological pattern of adult brainstem gliomas |
| Secondary | Molecular pattern of adult brainstem gliomas | 15 months | Description of the molecular pattern of adult brainstem gliomas |
| Secondary | Radiological pattern of adult brainstem gliomas based on standard and multimodal MRI | 15 months | Description of the radiological pattern of adult brainstem gliomas |
| Secondary | Metabolic pattern of adult brainstem gliomas based on 18F-DOPA PET CT at initial diagnosis and its change after treatment | 15 months | Description of the metabolic pattern of adult brainstem gliomas |
| Secondary | Volumetric velocity of the tumor growth before treatment start from the initial MRI until the last MRI before beginning of the treatment, established with sagittal cube FLAIR sequences | Approximatively one month (before beginning of treatment) | Description of the volumetric growth of adult brainstem gliomas before treatment |
| Secondary | Volumetric velocity of the tumor growth during treatment of chemotherapy, established with sagittal cube FLAIR sequences | 12 months | Description of the volumetric growth of adult brainstem gliomas before treatment |
| Secondary | Volumetric velocity of the tumor growth after treatment of chemotherapy, established with sagittal cube FLAIR sequences | up to 48 months | Description of the volumetric growth of adult brainstem gliomas after treatment |
| Secondary | Overall Survival | 15 months or later, up to 48 months |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03932981
GET https://conductscience.org/api/trials/v1/NCT03932981/registered